Evidence map›Paper›PMID 37451743›Full record

ReviewFEMS microbiology reviews2023

Faecalibacterium: a bacterial genus with promising human health applications.

Rebeca Martín, David Rios-Covian, Eugénie Huillet, Sandrine Auger, Sarah Khazaal, Luis G Bermúdez-Humarán, Harry Sokol, Jean-Marc Chatel, Philippe Langella

Open access · hybridAbstract readReview
In one paragraph

Review in FEMS microbiology reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 361 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
361citing papers in PubMed, 4 pooled it
66.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

361 citing papers in PubMed, 4 syntheses or guidelines pooled it, 434 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Nutrients · 2026
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

301 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rebeca MartínParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.
David Rios-CovianParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.
Eugénie HuilletParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.
Sandrine AugerParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.
Sarah KhazaalParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.
Luis G Bermúdez-HumaránParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.ORCID 0000-0001-7525-3131
Harry SokolParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.
Jean-Marc ChatelParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.
Philippe LangellaParis-Saclay University, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.ORCID 0000-0001-5960-4341
AgroParisTech · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In humans, many diseases are associated with alterations in gut microbiota, namely increases or decreases in the abundance of specific bacterial groups. One example is the genus Faecalibacterium. Numerous studies have underscored that low levels of Faecalibacterium are correlated with inflammatory conditions, with inflammatory bowel disease (IBD) in the forefront. Its representation is also diminished in the case of several diseases, including colorectal cancer (CRC), dermatitis, and depression. Additionally, the relative presence of this genus is considered to reflect, at least in part, intestinal health status because Faecalibacterium is frequently present at reduced levels in individuals with gastrointestinal diseases or disorders. In this review, we first thoroughly describe updates to the taxonomy of Faecalibacterium, which has transformed a single-species taxon to a multispecies taxon over the last decade. We then explore the links discovered between Faecalibacterium abundance and various diseases since the first IBD-focused studies were published. Next, we examine current available strategies for modulating Faecalibacterium levels in the gut. Finally, we summarize the mechanisms underlying the beneficial effects that have been attributed to this genus. Together, epidemiological and experimental data strongly support the use of Faecalibacterium as a next-generation probiotic (NGP) or live biotherapeutic product (LBP).

Indexed as

Gastrointestinal DiseasesGastrointestinal MicrobiomeInflammatory Bowel DiseasesBacteriaFaecalibacteriumHumansanaerobecommensalFaecalibacteriuminflammationkeystonelive biotherapeutic productnext-generation probiotic

Identifiers

PMID37451743
PMCPMC10410495
OpenAlexW4384276655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.